Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued on Wednesday, AnalystRatings.com reports. They currently have a $25.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 5.04% from the stock’s current price.
A number of other equities analysts have also weighed in on the stock. ValuEngine upgraded shares of Genmab A/S from a “sell” rating to a “hold” rating in a report on Tuesday. Morgan Stanley began coverage on Genmab A/S in a report on Monday, August 12th. They set an “overweight” rating for the company. Guggenheim began coverage on Genmab A/S in a research report on Monday, August 12th. They issued a “buy” rating on the stock. Bank of America upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a report on Friday, September 13th. Finally, Royal Bank of Canada assumed coverage on Genmab A/S in a research report on Monday, August 12th. They set an “outperform” rating and a $23.00 price target for the company. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Genmab A/S has a consensus rating of “Buy” and a consensus target price of $23.67.
Shares of GMAB stock opened at $23.80 on Wednesday. The company has a quick ratio of 18.72, a current ratio of 18.72 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $3.01 billion and a price-to-earnings ratio of 6.33. Genmab A/S has a one year low of $14.48 and a one year high of $24.50. The stock’s 50 day moving average is $22.06.
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
See Also: Key terms to understand channel trading
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.